Stock A287410 JEISYS MEDICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jeisys Medical Inc.

Equities

A287410

KR7287410005

Advanced Medical Equipment & Technology

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
12,260 KRW +1.91% Intraday chart for Jeisys Medical Inc. +2.51% +16.87%
Apr. 11 AVAVA Announces Exclusive Distribution Partnership with Jeisys Medical Inc. for Korea and Japan CI
Apr. 04 AVAVA, Inc. announced that it expects to receive $14.999999 million in funding from Jeisys Medical Inc. CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 552,979 606,355 789,504 924,784 - -
Enterprise Value (EV) 2 531 580.2 763.7 873.6 854.8 803.6
P/E ratio 43.9 x 22.9 x 32.6 x 23.4 x 18.6 x 15.5 x
Yield - - - - - -
Capitalization / Revenue 6.8 x 5.2 x 5.52 x 5.03 x 4.31 x 3.66 x
EV / Revenue 6.53 x 4.98 x 5.34 x 4.75 x 3.99 x 3.18 x
EV / EBITDA 21.5 x 15.5 x 18.8 x 16.2 x 12.2 x 9.71 x
EV / FCF 29.6 x 45.2 x 41.5 x 22.4 x 31.7 x 14 x
FCF Yield 3.37% 2.21% 2.41% 4.46% 3.15% 7.13%
Price to Book 11.8 x 7.65 x 8.31 x 6.79 x 5.12 x 3.82 x
Nbr of stocks (in thousands) 71,168 71,168 75,263 75,431 - -
Reference price 3 7,770 8,520 10,490 12,260 12,260 12,260
Announcement Date 2/3/22 3/7/23 3/14/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 81.3 116.5 143 183.8 214.3 252.7
EBITDA 1 24.74 37.35 40.58 54.04 69.87 82.77
EBIT 1 22.6 34.31 36.31 49.73 65.32 78.49
Operating Margin 27.8% 29.44% 25.39% 27.07% 30.48% 31.07%
Earnings before Tax (EBT) 1 12.09 34.16 35.5 49.52 64.66 78.08
Net income 1 10.09 27.32 24.8 38.7 50.52 61.35
Net margin 12.41% 23.44% 17.34% 21.06% 23.57% 24.28%
EPS 2 177.0 372.0 322.0 523.3 660.3 793.4
Free Cash Flow 3 17,910 12,823 18,387 39,000 26,940 57,333
FCF margin 22,031.09% 11,001.88% 12,855.42% 21,224% 12,569.61% 22,692.58%
FCF Conversion (EBITDA) 72,381.58% 34,327.13% 45,313.72% 72,163.98% 38,556.91% 69,269.54%
FCF Conversion (Net income) 177,457.15% 46,934.57% 74,140.09% 100,781.7% 53,326.28% 93,457.65%
Dividend per Share 2 - - - - - -
Announcement Date 2/3/22 3/7/23 3/14/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 22.39 25.33 30.77 28.64 31.8 35.16 39.11 39.66 43.96 43.1 43.1 45.7
EBITDA 1 - - - - - - - - 10.03 13.8 15.9 17.4
EBIT 1 5.684 8.549 8.962 7.716 9.087 9.648 10.22 8.829 8.86 11 11 14.1
Operating Margin 25.38% 33.74% 29.12% 26.94% 28.57% 27.44% 26.14% 22.26% 20.16% 25.52% 25.52% 30.85%
Earnings before Tax (EBT) 1 5.909 8.399 9.366 9.111 7.288 8.018 10.13 8.918 8.746 14.2 16.3 18.5
Net income 1 4.576 6.551 7.407 7.211 6.152 6.204 7.95 3.966 6.925 8.5 8.5 10.8
Net margin 20.43% 25.86% 24.07% 25.18% 19.34% 17.64% 20.33% 10% 15.76% 19.72% 19.72% 23.63%
EPS - - - - - - - - 90.00 - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 2/3/22 5/10/22 8/11/22 11/10/22 3/7/23 8/11/23 11/9/23 3/14/24 5/10/24 - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 21.9 26.2 25.9 51.2 70 121
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 2 17,910 12,823 18,387 39,000 26,940 57,333
ROE (net income / shareholders' equity) 31.2% 43.2% 28.4% 34.4% 31.4% 28.8%
ROA (Net income/ Total Assets) 17.8% 28.4% 19% 26.2% 23.6% 20.4%
Assets 1 56.61 96.09 130.2 147.7 214.1 300.7
Book Value Per Share 3 660.0 1,114 1,262 1,805 2,395 3,207
Cash Flow per Share 3 264.0 329.0 422.0 725.0 747.0 872.0
Capex 1 2.39 12.4 14.3 6.33 29 4
Capex / Sales 2.94% 10.66% 9.99% 3.45% 13.53% 1.58%
Announcement Date 2/3/22 3/7/23 3/14/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Jeisys Medical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12,260 KRW
Average target price
14,375 KRW
Spread / Average Target
+17.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
JEISYS MEDICAL INC. Stock Jeisys Medical Inc.
+16.87% 677M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+10.03% 223B
DANAHER CORPORATION Stock Danaher Corporation
+13.59% 195B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+20.01% 144B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+30.83% 111B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+2.05% 65.01B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+15.38% 53.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+3.96% 50.45B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+8.37% 44.15B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+3.27% 36.45B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. A287410 Stock
  4. Financials Jeisys Medical Inc.